Despite Target Cuts, Analysts Stick With Incyte for Big Upside

Health and Healthcare

Published: January 30, 2016 10:10 am

Last Updated: January 13, 2020 1:53 pm

Incyte Corp. (NASDAQ: INCY) took it on the chin this past week following the announcement that its Phase 2 trial of ruxolitinib would be stopped. This was detrimental to the stock, but a few analysts took a deeper look at it and realized that it might not be as bad as initially thought.

On Wednesday, the company announced that the Phase 2 sub-study of ruxolitinib or placebo in combination with regorafenib in patients with relapsed or refractory metastatic colorectal cancer and high C-reactive protein (CRP) will be stopped early.

The decision to stop the sub-study was made after a planned interim analysis of the high CRP subgroup demonstrated that ruxolitinib plus regorafenib did not show a sufficient level of efficacy to warrant continuation.

As a result, shares initially dropped as low as 14% off this level, pushing a new 52-week low. However after analysts came to bat for this biotech, shares made a healthy bounce in Friday’s trading session.

24/7 Wall St.
Biotech Is the Cheapest Since 2011: 4 Top Stocks to Buy Now

A few analysts weighed in on Incyte:

Merrill Lynch maintained a Buy rating but cut its price target to $87 from $145.
Credit Suisse has an Outperform rating but lowered its price target to $102 from $110.
Jefferies has a Buy rating but cut its price target to $106 from $141.
JMP Securities has an Outperform rating and lowered its price target to $100 from $133.
JPMorgan has an Overweight rating and lowered its price target to $115 from $125.
Leerink has an Outperform rating and cut its price target to $118 from $135.
UBS has a Buy rating but lowered its price target to $110 from $135.

Shares of Incyte were trading at $70.56 on Friday’s close, with a consensus analyst price target of $116.77 (this may change) and a 52-week trading range of $64.51 to $133.62.

Take Charge of Your Retirement In Just A Few Minutes (Sponsor)

Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance—and SmartAsset’s simple quiz makes it easier than ever for you to connect with a vetted financial advisor.

Here’s how it works:

Answer a Few Simple Questions. Tell us a bit about your goals and preferences—it only takes a few minutes!
Get Matched with Vetted Advisors Our smart tool matches you with up to three pre-screened, vetted advisors who serve your area and are held to a fiduciary standard to act in your best interests. Click here to begin
Choose Your Fit Review their profiles, schedule an introductory call (or meet in person), and select the advisor who feel is right for you.

Why wait? Start building the retirement you’ve always dreamed of. Click here to get started today!